PIK3CA and non-small cell lung carcinoma: Similarly, PTEN loss or PIK3CA mutations were shown to activate the AKT/mTOR pathway with subsequent increase of PD-L1 expression in melanoma and NSCLC [13] and treatment with specific PI3K inhibitors caused a reduction of PD-L1 expression [14].